Artiva Biotherapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $12.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar’s rating is based on several promising developments at Artiva Biotherapeutics, Inc. The company has prioritized refractory rheumatoid arthritis (reRA) as the lead indication for its AlloNK (AB-101) clinical development, which has recently received FDA Fast Track Designation. This designation highlights the significant unmet need for effective treatments in this patient population, as many remain refractory to existing therapies.
The AlloNK cells, combined with rituximab, have demonstrated impressive efficacy in previous studies, showing potential for deep and durable patient responses. Additionally, the treatment’s convenient administration and ongoing patient enrollment in various autoimmune studies further support the positive outlook. Artiva’s proactive engagement with the FDA regarding pivotal trial design and upcoming data readouts also contribute to the Buy rating, indicating a strategic path towards addressing critical needs in autoimmune diseases.
In another report released today, Needham also reiterated a Buy rating on the stock with a $18.00 price target.